-

Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited guests, the company will reschedule its planned March 31, 2020 Investor Day for a later date.

At this point, there isn’t a timetable for rescheduling the event and Pfizer will work within the context of appropriate guidance from health authorities to determine a future date.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contacts

Media Relations:
Amy Rose
+1 (212) 733-7410
Amy.Rose@Pfizer.com

Investor Relations:
Chuck Triano
+1 (212) 733-3901
Charles.E.Triano@Pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Relations:
Amy Rose
+1 (212) 733-7410
Amy.Rose@Pfizer.com

Investor Relations:
Chuck Triano
+1 (212) 733-3901
Charles.E.Triano@Pfizer.com

More News From Pfizer Inc.

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors...

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The...

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying con...
Back to Newsroom